Enclomiphene Citrate Cost in Nebraska 2026

What Is Enclomiphene Citrate and Why Do Nebraska Men Use It?

Enclomiphene citrate is the trans-isomer of clomiphene. It works at the hypothalamus by blocking estrogen receptors and stimulating the pituitary to release LH and FSH, which in turn raises endogenous testosterone without suppressing sperm production. That mechanism makes it attractive for men who want to preserve fertility while treating secondary hypogonadism, distinguishing it sharply from exogenous testosterone replacement therapy (TRT).

The drug gained significant research attention after Kim et al. (BJU Int, 2016) demonstrated that enclomiphene 12.5 mg and 25 mg daily raised serum testosterone from hypogonadal to eugonadal ranges in men with secondary hypogonadism while maintaining or improving sperm parameters, unlike TRT which predictably suppresses spermatogenesis 1. That single trial (N=124, 3-month follow-up) remains one of the most-cited controlled studies for this agent.

Secondary hypogonadism, also called hypogonadotropic hypogonadism, affects an estimated 2 to 4% of adult men when defined by a serum testosterone below 300 ng/dL with low or normal LH and FSH, per the American Urological Association's 2018 testosterone guideline 2. Nebraska has approximately 960,000 adult men based on 2023 US Census estimates, suggesting that tens of thousands may meet diagnostic criteria.

Enclomiphene is prescribed off-label in Nebraska because no standalone commercial product holds FDA approval. The FDA did review a New Drug Application for Androxal (enclomiphene 12.5 mg, 25 mg) but the agency declined to approve it. Prescribers may still legally write an off-label prescription, and 503A compounding pharmacies may fill it legally for an individual patient.

Enclomiphene Citrate Price in Nebraska: What to Expect in 2026

The average cash-pay price for compounded enclomiphene citrate from a licensed 503A pharmacy in Nebraska is approximately $90 per month for a standard dose of 12.5 to 25 mg daily. No commercial branded product carries a published retail price in Nebraska because no FDA-approved tablet is available at chain pharmacies.

Compare that to exogenous testosterone options: testosterone cypionate 200 mg/mL (10 mL vial) costs roughly $30, $80 at Nebraska retail pharmacies with a GoodRx coupon, but it suppresses spermatogenesis and requires hematocrit monitoring at intervals specified by the Endocrine Society's 2018 clinical practice guideline 3. For fertility-minded men, the $90/month compounded enclomiphene price may represent a clinically meaningful trade-off.

Price variation across Nebraska cities reflects pharmacy sourcing differences. A 503A pharmacy in Omaha may price a 30-day supply at $85, $100, while a mail-order 503A licensed in Nebraska might charge $80, $95 with a telehealth subscription bundled in. Quantities of 90 days sometimes bring per-month costs down by 10 to 15%, though 503A pharmacies cannot dispense more than a 90-day supply for a non-patient-specific bulk compound.

The Endocrine Society notes that testosterone deficiency treatment decisions should weigh both cost and the patient's reproductive goals 3. For men who want biological children within 12 to 24 months, an agent that preserves the HPG axis matters far more than a $30 monthly savings on injected testosterone.

HealthRX Nebraska Enclomiphene Cost Decision Framework

| Situation | Likely Best Path | Estimated Monthly Cost | |---|---|---| | Fertility-preservation goal, cash-pay | 503A compounded enclomiphene | ~$90 | | No fertility concern, cash-pay | Testosterone cypionate (generic) | $30, $80 | | Nebraska Medicaid enrollee | Enclomiphene not covered; discuss alternatives | N/A | | Private insurance, willing to appeal | Submit prior auth for off-label use; expect denial | $0 if approved, $90 cash fallback | | Telehealth subscription plan | Bundled enclomiphene + consult | $100, $180/month total |

Is Compounded Enclomiphene Citrate Legal in Nebraska?

Yes. A licensed 503A compounding pharmacy operating in Nebraska may legally compound enclomiphene citrate for an individual patient when a licensed prescriber writes a valid, patient-specific prescription. The FDA's framework for 503A pharmacies under the Drug Quality and Security Act of 2013 permits compounding of drugs that are not commercially available as approved products, provided the pharmacy meets state and federal standards 4.

Nebraska's pharmacy practice is governed by the Nebraska Department of Health and Human Services Pharmacy Division and Neb. Rev. Stat. section 38-2870 through 38-2888. 503A pharmacies must compound in response to a valid prescription for an identified individual patient. They cannot bulk-produce enclomiphene for office dispensing without that individual prescription.

503B outsourcing facilities operate under a different federal standard and may produce larger batches, but they supply clinics and hospitals rather than filling individual retail prescriptions directly. Most Nebraska men obtaining compounded enclomiphene will do so through a 503A pharmacy. Quality standards at 503A facilities vary; the FDA inspects 503B outsourcers more regularly than 503A sites, so patients should ask their pharmacy whether it is USP 795/797-compliant and undergoes third-party potency testing 4.

The American Society of Health-System Pharmacists states: "Compounding should occur only when there is a specific documented patient need that cannot be met by an FDA-approved commercial product" 5. Enclomiphene meets that criterion given the absence of an approved commercial tablet.

Nebraska Medicaid Coverage for Enclomiphene Citrate

Nebraska Medicaid does not cover enclomiphene citrate. The Nebraska Medicaid Preferred Drug List (PDL) as maintained by the Division of Medicaid and Long-Term Care does not include enclomiphene. Because no FDA-approved commercial product exists and the primary clinical application is off-label (secondary hypogonadism in men), Medicaid programs in most states treat it as a non-covered benefit.

Nebraska Medicaid does cover some testosterone preparations for documented hypogonadism. Testosterone cypionate injection (generic) appears on the PDL with prior authorization requirements tied to diagnostic criteria: typically two morning serum testosterone values below 300 ng/dL plus clinical symptoms consistent with the American Association of Clinical Endocrinology's position statement criteria 6.

If you are a Nebraska Medicaid enrollee and your clinician believes enclomiphene is medically necessary (for example, fertility preservation during hypogonadism treatment), a formal prior authorization with supporting documentation is theoretically possible but has a very low likelihood of approval under current PDL rules. An appeal citing the Kim et al. 2016 trial data 1 and any peer-reviewed meta-analyses would strengthen the case, but the HealthRX medical team is not aware of any Nebraska Medicaid precedent for enclomiphene approval.

Private Insurance Coverage for Enclomiphene in Nebraska

Private insurers in Nebraska, including Blue Cross Blue Shield of Nebraska, Medica, and United Healthcare plans sold on the ACA marketplace, do not list enclomiphene on their standard formularies as of 2025. The absence of an FDA-approved indication makes formulary inclusion unlikely without a formal New Drug Application approval.

Off-label prior authorization attempts occasionally succeed when a plan's medical policy allows for "medically necessary" off-label use with peer-reviewed evidence. The bar is high. A prescriber would need to document: (1) a confirmed diagnosis of secondary hypogonadism meeting AUA 2018 criteria 2, (2) failure or contraindication of covered alternatives, and (3) clinical need that distinguishes enclomiphene from testosterone (most commonly fertility preservation). Even with that documentation, denial rates for compounded drugs under private insurance are very high because most pharmacy benefit managers exclude compounded preparations from coverage altogether.

One practical path: if a patient has a Health Savings Account (HSA) or Flexible Spending Account (FSA), compounded enclomiphene qualifies as an eligible medical expense under IRS Publication 502 7, allowing pre-tax dollars to offset the $90/month cost.

Telehealth Prescribing of Enclomiphene Citrate in Nebraska

Nebraska permits telehealth prescribing of Schedule-unscheduled medications including enclomiphene, provided the prescriber establishes a valid patient-provider relationship. Enclomiphene is not a controlled substance under federal or Nebraska law, which simplifies the telehealth pathway considerably compared to, say, testosterone cypionate (Schedule III) or HCG.

Nebraska's telehealth statute (Neb. Rev. Stat. section 71-8505 et seq.) requires that a prescriber hold either a Nebraska license or a license recognized under interstate compact agreements before prescribing to a Nebraska patient. The Interstate Medical Licensure Compact (IMLC) covers Nebraska, meaning physicians licensed in any IMLC member state may obtain an expedited Nebraska license 8.

A typical telehealth workflow for enclomiphene in Nebraska looks like this:

1. Patient completes intake form and provides prior lab results or orders new labs (serum total testosterone, LH, FSH, CBC, comprehensive metabolic panel).
2. Synchronous or asynchronous video visit with a licensed prescriber.
3. Prescription transmitted electronically to a 503A pharmacy licensed in Nebraska or to a mail-order 503A that ships to Nebraska.
4. Follow-up labs at 6 to 12 weeks to confirm testosterone normalization and assess tolerability.

The Endocrine Society's 2018 guideline recommends confirming eugonadal testosterone levels (generally 400 to 700 ng/dL) at follow-up and monitoring for adverse effects including visual disturbances, which have been reported with the parent compound clomiphene 3. Enclomiphene carries fewer estrogenic effects than clomiphene because it lacks the cis-isomer (zuclomiphene), but visual symptom monitoring remains standard clinical practice.

Clinical Efficacy Data Supporting Enclomiphene Use

Prescribers in Nebraska citing enclomiphene for secondary hypogonadism rely on a limited but consistent evidence base. The key Phase 3 data from the Androxal NDA program showed that enclomiphene 12.5 mg and 25 mg daily raised morning serum testosterone to above 300 ng/dL in more than 75% of treated men within 3 months, compared to roughly 20% on placebo 9.

Kim et al. (BJU Int, 2016, N=124) reported mean serum testosterone increases from approximately 200 ng/dL at baseline to 400 to 500 ng/dL after 3 months on 12.5 mg daily, with sperm concentration either maintained or improved 1. That sperm-preservation finding is the single strongest clinical argument distinguishing enclomiphene from exogenous TRT, because exogenous testosterone suppresses intratesticular testosterone by up to 90% and reduces sperm concentration to azoospermic levels in approximately 40% of men within 6 months per the World Health Organization's male contraceptive trial data 10.

A 2019 analysis in Translational Andrology and Urology examined 296 hypogonadal men treated with clomiphene citrate (both isomers) and found that 71% achieved testosterone above 300 ng/dL at 4 to 6 weeks, with side effects including mood changes in 4.4% and visual symptoms in 1.1% of patients 11. While that study used racemic clomiphene rather than pure enclomiphene, the data inform expected tolerability given the shared trans-isomer mechanism.

The FDA's clinical review of the Androxal NDA noted that the drug met efficacy endpoints but raised questions about the adequacy of long-term cardiovascular and bone safety data, which contributed to the non-approval decision. The American Heart Association's 2022 advisory on testosterone therapy and cardiovascular risk 12 did not address enclomiphene specifically, but practitioners should apply similar cardiovascular risk screening given the testosterone-raising effect.

Baseline labs before starting enclomiphene should include: serum total testosterone (two morning draws), LH, FSH, prolactin (to rule out pituitary adenoma), estradiol, CBC, and PSA in men over 40. The PSA baseline matters because testosterone normalization may unmask subclinical prostate disease; the AUA and Endocrine Society both recommend PSA monitoring during testosterone-raising therapy 2 3.

Discount Programs and Ways to Lower Enclomiphene Costs in Nebraska

Several strategies can reduce the out-of-pocket burden for Nebraska patients:

Manufacturer and compounding pharmacy savings programs. Because no commercial product exists, traditional manufacturer copay cards do not apply. Some telehealth platforms that compound or source enclomiphene offer bundled subscription pricing that includes the consultation fee, pharmacy fill, and follow-up labs for $100, $180 per month total, which can be cheaper than paying separately.

GoodRx and similar discount cards. GoodRx pricing for compounded preparations is not standardized and depends on the individual 503A pharmacy's participation. Calling ahead to Omaha- or Lincoln-area 503A pharmacies to ask whether they accept GoodRx or similar cards is worth the five-minute effort. Savings of 10 to 20% are occasionally available.

HSA and FSA dollars. As noted, IRS Publication 502 classifies prescription medications including compounded drugs as eligible medical expenses 7. Using pre-tax HSA dollars on a $90/month prescription saves $22, $31/month for a taxpayer in the 25 to 35% federal bracket.

90-day supply. Asking the 503A pharmacy for a 90-day fill, when the prescriber writes for that quantity, reduces per-unit dispensing fees and may lower effective monthly cost by $5, $15.

Nebraska drug assistance programs. Nebraska does not operate a state pharmaceutical assistance program for working-age adults with secondary hypogonadism. The Nebraska Department of Health and Human Services does administer CHIP and Medicaid, neither of which covers enclomiphene. The NeedyMeds database 13 lists disease-based assistance programs; as of mid-2025, no enclomiphene-specific program appears there, but checking at the time of prescription is advisable because programs change.

Monitoring and Follow-Up Expectations in Nebraska

After starting enclomiphene, standard practice calls for repeat labs at 6 weeks (serum testosterone, LH, FSH, estradiol) and again at 3 months. The target range per Endocrine Society 2018 guidance is a mid-normal testosterone of roughly 400 to 700 ng/dL 3. If testosterone remains below 300 ng/dL at 12 weeks on 25 mg daily, the prescriber should reassess whether the diagnosis is truly secondary rather than primary hypogonadism, because enclomiphene will not raise testosterone when the testes themselves cannot respond to gonadotropin stimulation.

Annual follow-up labs for men on ongoing enclomiphene therapy should mirror those recommended for men on testosterone therapy: testosterone, hematocrit, PSA (age-appropriate), and a symptom review. Hematocrit elevation (above 54%) is less common with enclomiphene than with exogenous testosterone but has been reported in case literature when testosterone rises significantly 11.

Nebraska telehealth prescribers typically build follow-up visits into their subscription model. Ask specifically whether the plan covers lab result review asynchronously or requires a paid synchronous visit, because that difference affects annual cost by $100, $300.

How Nebraska Providers Write an Enclomiphene Prescription

A Nebraska-licensed physician, nurse practitioner, or physician assistant may prescribe enclomiphene off-label for secondary hypogonadism. The prescription should specify:

• Drug name: enclomiphene citrate (not clomiphene citrate, which is the racemic mixture)
• Dose: 12.5 mg or 25 mg
• Dose form: oral capsule (most common at 503A pharmacies)
• Frequency: once daily
• Quantity: 30 or 90 capsules
• Refills: typically zero to three; the prescriber will reassess at follow-up

Writing "enclomiphene citrate" explicitly prevents the pharmacy from substituting racemic clomiphene, which contains the cis-isomer zuclomiphene and carries a higher risk of estrogenic side effects including mood changes and visual disturbances per comparative pharmacology data 1.